CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing FacilityBusiness Wire • 10/22/21
CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And InvestorsSeeking Alpha • 07/14/21
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021Business Wire • 06/30/21
CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer PatientsBenzinga • 06/28/21
CEL-SCI's Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 StudyBusiness Wire • 06/28/21
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder MeetingBusiness Wire • 06/25/21